A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
Bibliographic record
Abstract
Plain Language SummaryWhat were the results?After 58.7 months (or approximately 5 years) from when participants started the study, more participants who received D-VRd had no signs of multiple myeloma in their bone marrow and were more likely to be alive and free from their multiple myeloma getting worse compared with participants who only received VRd. While some unwanted or undesirable effects of treatment, known as ‘side effects,’ were higher with D-VRd than VRd (such as infections), participants in both treatment groups experienced some side effects, and side effects were similar to those already known for these types of medicines.What do the results of the study mean?The results of the CEPHEUS study showed that among adults with a new diagnosis of multiple myeloma who could not have or did not want to have a transplant, participants who received the combination of D-VRd had better responses to treatment and lived longer free from worsening multiple myeloma compared with those who received only VRd. In addition, there were no unexpected side effects in either treatment group.The purpose of this plain language summary is to help you to understand the findings from recent research.Daratumumab is used to treat the disease under study that is discussed in this summary, multiple myeloma. Approvals for the use of daratumumab, either alone or in combination with other treatments, to treat multiple myeloma vary by country and region; therefore, please check with your local health care provider for more details.The results of this study may differ from those of other studies. Health care professionals should make treatment decisions based on all available evidence, not on the results of a single study.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.011 | 0.051 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.003 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.004 | 0.004 |
| Insufficient payload (model declined to judge) | 0.131 | 0.032 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".